for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-VBL Therapeutics Announces The Launch Of A New Clinical Trial Of VB-111 Combined With The Checkpoint Inhibitor, Nivolumab, In Metastatic Colorectal Cancer

Feb 20 (Reuters) - Vascular Biogenics Ltd:

* VBL THERAPEUTICS ANNOUNCES THE LAUNCH OF A NEW CLINICAL TRIAL OF VB-111 COMBINED WITH THE CHECKPOINT INHIBITOR, NIVOLUMAB, IN METASTATIC COLORECTAL CANCER

* VASCULAR BIOGENICS LTD - NATIONAL CANCER INSTITUTE WILL SERVE AS INVESTIGATIONAL NEW DRUG (IND) SPONSOR FOR THIS STUDY Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up